PMID- 29421316
OWN - NLM
STAT- MEDLINE
DCOM- 20190920
LR  - 20231213
IS  - 2213-7173 (Electronic)
IS  - 2213-7165 (Linking)
VI  - 13
DP  - 2018 Jun
TI  - In vitro activity of novel anti-MRSA cephalosporins and comparator antimicrobial 
      agents against staphylococci involved in prosthetic joint infections.
PG  - 221-225
LID - S2213-7165(18)30024-9 [pii]
LID - 10.1016/j.jgar.2018.01.022 [doi]
AB  - OBJECTIVES: Ceftaroline and ceftobiprole are new parenteral cephalosporins with 
      potent activity against methicillin-resistant (MR) staphylococci, which are the 
      leading cause of prosthetic joint infections (PJIs). The aim of this study was to 
      determine and compare the in vitro activities of both molecules against 
      staphylococcal isolates recovered from clinically documented PJIs. METHODS: A 
      collection of 200 non-duplicate clinical isolates [100 Staphylococcus aureus and 
      100 coagulase-negative staphylococci (CoNS), including 19 and 27 MR isolates, 
      respectively] was studied. Minimum inhibitory concentrations (MICs) of oxacillin, 
      ceftaroline, ceftobiprole, vancomycin, teicoplanin, clindamycin, levofloxacin, 
      linezolid and daptomycin were determined by the broth microdilution method. 
      Bactericidal activity (at 4x MIC) of ceftaroline, ceftobiprole, vancomycin, 
      teicoplanin, linezolid and daptomycin was assessed by time-kill assay. RESULTS: 
      Among the S. aureus isolates, 100% were susceptible to ceftaroline (MIC(50/90), 
      0.25/0.5mug/mL) and 98% were susceptible to ceftobiprole (MIC(50/90), 0.5/1mug/mL), 
      regardless of their methicillin resistance. The two ceftobiprole-non-susceptible 
      strains (including one MRSA) showed MICs at 4mg/L. Against CoNS isolates, 
      ceftaroline and ceftobiprole exhibited in vitro potency with MIC(50/90) values at 
      0.06/0.25mug/mL and 0.25/1mug/mL, respectively. At 4x MIC, ceftaroline and 
      ceftobiprole showed rapid and marked bactericidal activity against both S. aureus 
      and CoNS (after 24/12h and 12/6h of incubation, respectively), whilst none of the 
      other molecules tested had a bactericidal effect by 24h. CONCLUSIONS: This study 
      showed that ceftaroline and ceftobiprole have excellent in vitro activity against 
      clinical isolates of staphylococci involved in PJIs. These molecules may 
      therefore represent promising alternatives for the treatment of such infections.
CI  - Copyright (c) 2018 International Society for Chemotherapy of Infection and Cancer. 
      Published by Elsevier Ltd. All rights reserved.
FAU - Isnard, Christophe
AU  - Isnard C
AD  - CHU de Caen, Service de microbiologie, Caen, France; Universite de Caen 
      Normandie, EA4655 U2RM (equipe 'Antibio-resistance'), Caen, France.
FAU - Dhalluin, Anne
AU  - Dhalluin A
AD  - Universite de Caen Normandie, EA4655 U2RM (equipe 'Antibio-resistance'), Caen, 
      France.
FAU - Malandain, Damasie
AU  - Malandain D
AD  - CHU de Caen, Service de microbiologie, Caen, France.
FAU - Bruey, Quentin
AU  - Bruey Q
AD  - Universite de Caen Normandie, EA4655 U2RM (equipe 'Antibio-resistance'), Caen, 
      France.
FAU - Auzou, Michel
AU  - Auzou M
AD  - CHU de Caen, Service de microbiologie, Caen, France.
FAU - Michon, Jocelyn
AU  - Michon J
AD  - CHU de Caen, Service des maladies infectieuses, Caen, France.
FAU - Giard, Jean-Christophe
AU  - Giard JC
AD  - Universite de Caen Normandie, EA4655 U2RM (equipe 'Antibio-resistance'), Caen, 
      France.
FAU - Guerin, Francois
AU  - Guerin F
AD  - CHU de Caen, Service de microbiologie, Caen, France; Universite de Caen 
      Normandie, EA4655 U2RM (equipe 'Antibio-resistance'), Caen, France.
FAU - Cattoir, Vincent
AU  - Cattoir V
AD  - CHU de Rennes, Service de bacteriologie-hygiene hospitaliere, Rennes, France; CNR 
      de la resistance aux antibiotiques (laboratoire associe 'Enterocoques'), Rennes, 
      France. Electronic address: vincent.cattoir@chu-rennes.fr.
LA  - eng
PT  - Journal Article
DEP - 20180205
PL  - Netherlands
TA  - J Glob Antimicrob Resist
JT  - Journal of global antimicrobial resistance
JID - 101622459
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Cephalosporins)
RN  - 5T97333YZK (ceftobiprole)
RN  - 6Q205EH1VU (Vancomycin)
RN  - NWQ5N31VKK (Daptomycin)
SB  - IM
MH  - Anti-Bacterial Agents/*pharmacology
MH  - Cephalosporins/*pharmacology
MH  - Daptomycin/pharmacology
MH  - Humans
MH  - Joint Diseases/*microbiology
MH  - Methicillin-Resistant Staphylococcus aureus/*drug effects/isolation & 
      purification
MH  - Microbial Sensitivity Tests
MH  - Prosthesis-Related Infections/*microbiology
MH  - Staphylococcal Infections/microbiology
MH  - Staphylococcus/*drug effects
MH  - Staphylococcus aureus/drug effects
MH  - Vancomycin/pharmacology
MH  - Ceftaroline
OTO - NOTNLM
OT  - Ceftaroline
OT  - Ceftobiprole
OT  - CoNS
OT  - PJI
OT  - Prosthetic joint infection
OT  - Staphylococcus aureus
EDAT- 2018/02/09 06:00
MHDA- 2019/09/21 06:00
CRDT- 2018/02/09 06:00
PHST- 2017/08/07 00:00 [received]
PHST- 2018/01/22 00:00 [revised]
PHST- 2018/01/29 00:00 [accepted]
PHST- 2018/02/09 06:00 [pubmed]
PHST- 2019/09/21 06:00 [medline]
PHST- 2018/02/09 06:00 [entrez]
AID - S2213-7165(18)30024-9 [pii]
AID - 10.1016/j.jgar.2018.01.022 [doi]
PST - ppublish
SO  - J Glob Antimicrob Resist. 2018 Jun;13:221-225. doi: 10.1016/j.jgar.2018.01.022. 
      Epub 2018 Feb 5.